Clinical Trial Update: PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia [Phase 2]

View source ↗

Summary

Phase 2 study assessing PK, pharmacodynamics, safety and immunogenicity of Spectrila in adults with acute lymphoblastic leukemia (B-cell) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Spectrila (pegaspargase)

Snippet

Sponsor: medac GmbH | Conditions: Acute B-Cell Lymphoblastic Leukaemia | Phase 2 | Status: TERMINATED